肝硬化
内科学
非酒精性脂肪肝
脂肪性肝炎
脂肪肝
脂肪变性
内分泌学
医学
纤维化
胰岛素抵抗
肝移植
胰岛素
疾病
移植
作者
Laura E. Dichtel,Jose Cordoba-Chacon,Rhonda D. Kineman
标识
DOI:10.1210/clinem/dgac088
摘要
Patients with obesity have a high prevalence of nonalcoholic fatty liver disease (NAFLD), representing a spectrum of simple steatosis to nonalcoholic steatohepatitis (NASH), without and with fibrosis. Understanding the etiology of NAFLD is clinically relevant since NAFLD is an independent risk factor for diabetes and cardiovascular disease. In addition, NASH predisposes patients to the development of cirrhosis and hepatocellular carcinoma, and NASH cirrhosis represents the fastest growing indication for liver transplantation in the United States. It is appreciated that multiple factors are involved in the development and progression of NAFLD. Growth hormone (GH) and insulin-like growth factor 1 (IGF1) regulate metabolic, immune, and hepatic stellate cell function, and alterations in the production and function of GH is associated with obesity and NAFLD/NASH. Therefore, this review will focus on the potential role of GH and IGF1 in the regulation of hepatic steatosis, inflammation, and fibrosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI